Therapeutic inertia and intensified treatment in diabetes mellitus prescription patterns: A nationwide population-based study in Taiwan

Li-Ying Huang1,2, Hseng-Long Yeh3,4, Ming-Chin Yang2, Wen-Yi Shau1, Syi Su2 and Mei-Shu Lai5

Abstract

Objective: To measure therapeutic inertia by characterizing prescription patterns using secondary data obtained from the nationwide diabetes mellitus pay-for-performance (DM-P4P) programme in Taiwan.

Methods: Using reimbursement claims from Taiwan’s National Health Insurance Research Database, a nationwide retrospective cohort study was undertaken of patients with diabetes mellitus who participated in the DM-P4P programme from 2006–2008. Glycosylated haemoglobin results were used to evaluate modifications in therapy in response to poor diabetes control. Prescription patterns were used to assign patients to either a therapeutic inertia group or an intensified treatment group. Therapeutic inertia was defined as the failure to act on a known problem.

Results: The research sample comprised of 168,876 patients with diabetes mellitus who had undergone 899,135 tests. Of these, 37.4% (336,615 visits) of prescriptions were for a combination of two types of drug and 27.7% (248,788 visits) were for a combination of three types of drug.

1Division of Health Technology Assessment, Centre for Drug Evaluation, Taipei, Taiwan
2Graduate Institute of Health Care Organization Administration, College of Public Health, National Taiwan University, Taipei, Taiwan
3School of Public Health, College of Public Health and Nutrition, Taipei Medical University, Taipei, Taiwan
4Department of Cardiology, Sijih Cathay General Hospital, Taipei, Taiwan
5Institute of Epidemiology and Preventive Medicine, College of Public Health, National Taiwan University, Taiwan

Data from this paper were published in abstract form in Pharmacoepidemiol Drug Saf 2014; 23(S1):62.

Corresponding author:
Mei-Shu Lai, Institute of Epidemiology and Preventive Medicine, College of Public Health, National Taiwan University, Taiwan, 17 Xu-Zhou Road, Taipei 10020, Taiwan.
Email: mslai@ntu.edu.tw

Creative Commons CC-BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 3.0 License (http://www.creativecommons.org/licenses/by-nc/3.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage).
The proportion of patients in the intensified therapy group who were prescribed more than two types of drug was considerably higher than that in the therapeutic inertia group.

**Conclusion:** In many cases in the therapeutic inertia group only a single type of hypoglycaemic drug was prescribed or the dosage remained unchanged.

**Keywords**
Therapeutic inertia, intensified therapy, glycosylated haemoglobin (HbA1c), prescription pattern, diabetes mellitus

Date received: 16 February 2016; accepted: 18 July 2016

**Introduction**
It has been reported that more than 387 million people worldwide suffer from diabetes mellitus, and that this figure is expected to increase to over 438 million by 2030.1,2 Diabetes mellitus is a major challenge to Asian countries, including Taiwan.3 Despite guidelines that emphasize the importance of glycaemic control among patients with diabetes mellitus, many patients have glycosylated haemoglobin (HbA1c) levels outside the recommended range.4–6 Therapeutic inertia is defined as when a physician does not begin or intensify treatment when this is deemed necessary according to current clinical practice guidelines.7–9 Previous studies have shown that patients enrolled in the diabetes mellitus pay-for-performance (DM-P4P) programme in Taiwan are more likely to undergo guideline-recommended tests and examinations.10–13 Because the DM-P4P programme is a physician-level incentive strategy aimed at improving care quality, profiling and comparing the quality of care provided by various physician groups is a valuable strategy to facilitate this improvement.14 Our previous study found that 38.5% of the patients were subject to therapeutic inertia.6 Furthermore, patients at medical centres were shown to be more likely to be prescribed with intensified treatment than patients in primary clinics.6 The primary goal of this study was to investigate differences between diabetes prescription patterns for patients subject to therapeutic inertia and those with intensified treatment.

**Patients and methods**

**Description of the study population**
In this retrospective cohort study, all patients who were categorized according to the International Statistical Classification of Diseases and Related Health Problems as code 250,15 and who had made at least four outpatient visits each year from 1 January 2006 to 31 December 2008 were enrolled.16 This selection process has been reported to increase the accuracy of the diagnosis by 99.16 times compared with a selection process that included patients with one or fewer outpatient visits per year.16 HbA1c results were used to evaluate the therapy modifications adopted in response to poor diabetes control (i.e., HbA1c values were 7%–11%). Secondary data did not include changes in insulin dosage, and therefore the patients using insulin prior to the HbA1c tests were excluded. The influence of comorbidities on time to intensification was evaluated using the chronic illness with complexity (CIC) score.17 A diabetes comorbidity severity index (DCSI) score was calculated for diabetes-related comorbid disease conditions.18

**Data sources**
The study used several administrative databases detailing health service usage in
Taiwan, including the National Health Insurance (NHI) Research Database (NHIRD) and the virtual private network of the DM-P4P database. The DM-P4P programme was designed by the NHI Bureau in Taiwan, and it is the most comprehensive and mature P4P programme in Taiwan. Participation in the programme was voluntary, and the DM-P4P database was constructed to supplement regular NHI claims data. DM-P4P patient outcome data such as HbA$_{1c}$ values were reported by the hospitals and entered into the P4P-specific database automatically. This study was approved by the Research Ethics Committee of National Taiwan University Hospital, Taiwan (no. 201203010R1C). Signed informed consent was not required because this study used anonymized data and did not involve any human experimentation.

**Pharmacological management**

In this study, pharmacological therapy was defined as prescriptions filled 120 days before and after receiving HbA$_{1c}$ test results. Antihyperglycaemic agents were evaluated according to the Anatomical Therapeutical Chemical Classification Defined Daily Dose (ATC/DDD) system developed by the World Health Organization. Antihyperglycaemic agents were categorized as insulin (ATC codes: A10AB, A10AC, A10AD, A10AE) and the following 17 major classes of oral antihyperglycaemic agent (ATC codes are listed outside parentheses): A10BB (sulfonamides, urea derivatives), including A10BB01 to A10BB12 (i.e., glibenclamide, chlorpropamide, tolazamide, glibenclamide, gliclazide, glimepiride); A10BD02 (metformin and sulfonylamides); A10BA02 (metformin); A10BA03 (bufometin); A10BD03 (metformin and rosiglitazone); A10BF01 (acarbose); A10BG02 (rosiglitazone); A10BG03 (pioglitazone); A10BX01 (gum); A10BX02 (repaglinide); and A10BX03 (nateglinide).

**Analysis**

Medications were quantified by assigning DDD units to each item from the NHIRD based on the index of the ATC classification system. When used for the identification of changes in prescription (P$_{after}$–P$_{before}$), the prescribed total DDD was generally comprised of the 17 major classes. When prescription medications from more than one class were considered, any increase in the dosage among any of the drugs was considered as intensified therapy.

**Measurements**

In this study, the following prescription changes that occurred following HbA$_{1c}$ measurements were classified into four mutually exclusive groups: group 1, the addition of one or more new classes of drug; group 2, an increase in the dosage of the same drugs used prior to HbA$_{1c}$ measurements; group 3, no change in the drug class or a decrease in the dosage (DDD); group 4, discontinuation of drug therapy.

**Definition of intensified therapy**

Any change in prescription according to the following conditions was defined as intensified therapy: the prescription of new oral antihyperglycaemic agents, increasing the dosage of any current medication, switching to another medication in a different therapeutic class, or the initiation of insulin use. The study did not treat switches to medications in the same therapeutic class as therapy modification unless the DDD of the new agent was more than that of the previous agent, because switching medications could be a response to side effects rather than intensifying the therapy.
Statistical analyses

All statistical analyses were performed using the Statistical Analysis System (SAS) version 9.3. (SAS Institute, Cary, NC, USA). Descriptive statistical analyses were used to examine modifications in therapy to identify therapeutic inertia. χ²-test for categorical variables were used to compare groups (intensified therapy and therapeutic inertia) on key variables obtained from the NHIRD data set. A P-value < 0.05 was considered statistically significant.

Results

Following the exclusion of ineligible patients, the research sample comprised of data from 168 876 patients with diabetes mellitus. Among the 899 135 tests that revealed HbA₁c levels ranging from 7% to 11%, 61.65% of the patients (554 320 visits) had their therapy intensified, compared with 38.35% (344 815 visits) who did not.6 The mean ± SD age of the patients was 60.5 ± 10.8 years. The proportion of patients with HbA₁c levels between 7% and 8% was 48.1% (432 305 visits) (Table 1). This study identified the following clinical characteristics that were significantly different between the intensified therapy group and the therapeutic inertia group: age, HbA₁c levels, DCSI scores, and CIC count (P < 0.001 for all four characteristics).

Patients were prescribed new drugs in 42.0% (377 675 visits) of all case visits, and 19.5% (175 239 visits) of the case visits involved an increase in dosage of the same drug class. Among the therapeutic inertia group, 72.5% (250 077 visits) of the prescriptions were for the same medication despite abnormal HbA₁c results. Regarding the pattern analysis of antihyperglycaemic agents, 37.4% (336 615 visits) of the studied prescriptions were for a combination of two types of drug, 27.7% (248 788 visits) were for a combination of three types of drug, and 13.3% (119 424 visits) were for a monotherapy regimen (Table 2). Among the monotherapy prescriptions, sulfonamides were the most frequently prescribed types of medication (64.4%; 76 937 visits), and insulin monotherapy accounted for only 7.3% (8672 visits) of the prescriptions (Table 2). Sulfonamides and biguanides were the most frequently prescribed drugs for polytherapy involving two types of drug, accounting for 78.9% (265 563 visits) of all dual-drug prescriptions.

Among the polytherapy prescriptions involving three types of drug (248 788 of 899 135 visits; 27.7%), sulfonamide, biguanide, and thiazolidinedione (109 680 of 248 788 visits; 44.1%) were the most frequently prescribed combination (Table 2). An additional 8.3% (20 597 of 248 788 visits) of the prescriptions were for a combination of oral antihyperglycaemic agents and insulin. The proportion of patients in the intensified therapy group prescribed more than two types of drug was considerably higher than that in the therapeutic inertia group. For example, 70.7% (175 989 of 248 788 visits) of the cases in the intensified therapy group were prescribed a combination of three types of drug, whereas only 29.3% (72 799 of 248 788 visits) of the patients in the therapeutic inertia group were prescribed such a combination (Table 2). In addition, 38.3% (45 694 of 119 424 visits) of the patients in the intensified therapy group received monotherapy, among whom 8672 single drug prescriptions (of 45 694 visits; 19.0%) were for insulin. However, 61.7% (73 730 of 119 424 visits) of the patients in the therapeutic inertia group received monotherapy (Table 2).

Discussion

Therapeutic inertia is defined as a lack of treatment intensification despite a suboptimal outcome with the current diabetes management strategy.9 In the present study in a real-world Taiwanese population, based
on data from more than 899,000 visits, the following patient characteristics were significantly different between the intensified therapy group and the therapeutic inertia group: age, HbA1c levels, DCSI scores, and CIC count. Treatment of type 2 diabetes mellitus typically begins with lifestyle adjustments and oral antidiabetic drugs.20–23 When blood glucose can no longer be controlled merely through lifestyle changes, metformin is typically prescribed as a first-line medication, particularly for patients who are also overweight.21–24 However, because diabetes is a progressive disease, blood glucose concentration worsens with time, and most patients with diabetes eventually need at least two types of oral medication or insulin to reach or maintain the required blood glucose level.22,23 Current treatment guidelines differ in terms of what second-line medication should be prescribed in cases where blood glucose can no longer be controlled through metformin alone.21,22 Some recommend supplementing metformin

| Characteristics                | Total prescriptions | Intensified therapy group | Therapeutic inertia group | Statistical significance^a |
|--------------------------------|---------------------|---------------------------|---------------------------|-----------------------------|
| Age                            | 899,135 (100.00%)   | 554,320 (61.65%)          | 344,815 (38.35%)          |                             |
| <40 years                      | 29,059 (3.23%)      | 19,754 (3.56%)            | 9,305 (2.70%)             |                             |
| ≥40 and <65 years              | 522,397 (58.10%)    | 322,236 (58.13%)          | 200,161 (58.05%)          |                             |
| ≥65 and <80 years              | 347,679 (38.67%)    | 212,330 (38.30%)          | 135,349 (39.25%)          |                             |
| Sex                            |                     |                           |                           |                             |
| Male                           | 412,143 (45.84%)    | 254,156 (45.85%)          | 157,987 (45.82%)          |                             |
| HbA1c levels                   |                     |                           |                           |                             |
| 7 ≤ HbA1c < 8                  | 432,305 (48.08%)    | 234,619 (42.33%)          | 197,686 (57.33%)          | P < 0.001                   |
| 8 ≤ HbA1c < 9                  | 250,293 (27.84%)    | 161,507 (29.14%)          | 88,786 (25.75%)           |                             |
| 9 ≤ HbA1c < 10                 | 139,336 (15.50%)    | 98,775 (17.82%)           | 40,561 (11.76%)           |                             |
| 10 ≤ HbA1c < 11                | 77,201 (8.59%)      | 59,419 (10.72%)           | 17,782 (5.16%)            |                             |
| DCSI score (DM severity)       |                     |                           |                           |                             |
| 0                              | 813,345 (90.46%)    | 496,194 (89.51%)          | 317,151 (91.98%)          | P < 0.001                   |
| 1                              | 49,508 (5.51%)      | 32,390 (5.84%)            | 17,118 (4.96%)            |                             |
| 2                              | 30,330 (3.37%)      | 21,219 (3.83%)            | 9,111 (2.64%)             |                             |
| 3                              | 4,033 (0.45%)       | 2,989 (0.54%)             | 1,044 (0.30%)             |                             |
| 4+                             | 1,919 (0.21%)       | 1,528 (0.28%)             | 391 (0.11%)               |                             |
| CIC count (DM comorbidity)     |                     |                           |                           |                             |
| 0                              | 848,499 (94.37%)    | 521,024 (93.99%)          | 327,475 (94.97%)          | P < 0.001                   |
| 1                              | 48,088 (5.35%)      | 31,415 (5.67%)            | 16,673 (4.84%)            |                             |
| 2                              | 23,494 (0.26%)      | 17,500 (0.32%)            | 5,999 (0.17%)             |                             |
| 3                              | 180 (0.02%)         | 116 (0.02%)               | 64 (0.02%)                |                             |
| 4+                             | 19 (0.00%)          | 15 (0.00%)                | 4 (0.00%)                 |                             |

Data presented as n of visits (%).
^aχ²-test was used to compare groups (intensified therapy and therapeutic inertia) on key variables obtained from the National Health Insurance Research Database data set.
HbA1c, glycosylated haemoglobin; DCSI, diabetes comorbidity severity index; DM, diabetes mellitus; CIC, chronic illness with complexity; NS, no significant between-group difference (P ≥ 0.05).
with sulfonylurea or gradually adding other types of drug. For example, compared with the UK, Canada, and Australia, the NHI regulations in Taiwan are not as strict and do not differentiate between first- and second-line drugs, which allowed physicians to freely choose what drug or combination of drugs they prescribed as first-line medication before May 2016. Most single-drug prescriptions in Taiwan are for sulfonamide rather than metformin. In this present study, the most frequently prescribed monotherapy drug was sulfonylurea, and metformin combined with sulfonylurea for polytherapy. In addition, this present study found that of the drug prescriptions for patients, 37.4% (336 615 visits) were for two types of drug, 27.7% (248 788 visits) were for three types of drug, and 13.3% (119 424 visits) were for monotherapy. This present study also observed that in the intensified therapy group, the percentage of patients who were prescribed more than two types of drug was considerably higher than that in the therapeutic inertia group. For example, for the three oral drug combination group, 70.7% of the prescriptions were from patients in the intensified therapy group. In the therapeutic inertia group, however, the present study observed that in many cases only a single type of hypoglycaemic drug was prescribed, or that the dosage remained unchanged. Few studies have discussed switching drug types in intensified therapy. A retrospective

### Table 2. Prescribing patterns in patients \( (n = 168\,876) \) with diabetes mellitus who underwent intensified therapy or therapeutic inertia and who provided prescription data \( (n = 899\,135) \) for this study as part of the diabetes mellitus pay-for-performance (DM-P4P) programme in Taiwan.

| Drug classes | Total prescriptions \( n = 899\,135 \) | Intensified therapy group \( n = 554\,320 \) | Therapeutic inertia group \( n = 344\,815 \) |
|--------------|----------------------------------|----------------------------------|----------------------------------|
| Monotherapy  | 119 424 (13.3%)                  | 45 694 (8.2%)                    | 73 730 (21.4%)                  |
| A10BB Sulfonamides | 76 937 (64.4%)                  | 26 539 (58.1%)                  | 50 398 (68.4%)                  |
| A10BA Biguanides   | 26 018 (21.8%)                  | 9102 (19.9%)                    | 16 916 (22.9%)                  |
| Insulin          | 8672 (7.3%)                     | 8672 (19.0%)                    | 0 (0.0%)                        |
| A10BG Thiazolidinediones | 942 (0.8%)                      | 333 (0.7%)                      | 609 (0.8%)                      |
| Others           | 6 855 (5.7%)                    | 1048 (2.3%)                     | 5807 (7.9%)                     |
| Two oral drug combinations | 336 615 (37.4%)                  | 178 901 (32.3%)                 | 157 714 (45.7%)                 |
| Sulfonamides + Biguanides | 265 563 (78.9%)                  | 147 372 (82.4%)                 | 118 191 (74.9%)                 |
| Sulfonamides + TZD | 26 778 (8.0%)                    | 12 648 (7.1%)                   | 14 130 (9.0%)                   |
| Others + Insulin  | 2907 (0.9%)                     | 2907 (1.6%)                     | 0 (0.0%)                        |
| Others           | 41 367 (12.3%)                  | 15 974 (8.9%)                   | 25 393 (16.1%)                  |
| Three oral drug combinations | 248 788 (27.7%)                  | 175 989 (31.7%)                 | 72 799 (21.1%)                  |
| Sulfonamides + Biguanides + TZD | 109 680 (44.1%)                  | 72 857 (41.4%)                 | 36 823 (50.6%)                  |
| Sulfonamides + Biguanides + Others | 75 613 (30.4%)                  | 58 868 (33.4%)                 | 16 745 (23.0%)                  |
| Sulfonamides + Others + TZD | 13 146 (5.3%)                    | 9273 (5.3%)                     | 3873 (5.3%)                     |
| Biguanides + Others + TZD | 6956 (2.8%)                      | 4313 (2.5%)                     | 2643 (3.6%)                     |
| Sulfonamides + Biguanides + Insulin | 20 597 (8.3%)                    | 20 597 (11.7%)                 | 0 (0.0%)                        |
| Others           | 22 796 (9.2%)                    | 10 081 (5.7%)                   | 12 715 (17.5%)                  |
| Four or more drugs | 152 554 (17.0%)                  | 144 928 (26.1%)                 | 7626 (2.2%)                     |
| No drugs         | 41 754 (4.6%)                    | 8808 (1.6%)                     | 32 946 (9.6%)                   |

Data presented as \( n \) of visits (%). Others, A10BX02 repaglinide, A10BF01 acarbose and A10BX03 nateglinide; TZD, thiazolidinedione.
A cohort study involving 253,238 patients was undertaken to assess the number of cases where drug treatment had been modified in the previous 6 months because of a failure to properly control one or more types of chronic disease. The authors reported that 66% of the patients with poorly controlled HbA1c levels had their prescription medication changed. Most changes involved prescribing other types of drug (70% to 84% of cases) or increasing the prescribed dosage (15% to 40% of cases). Similar to the results reported by research conducted in Taiwan, this present research group previously found that 61.5% of prescriptions were modified before and after a test result of HbA1c > 7%. New types of drug were added in 42.0% of cases (377,675 prescriptions), and dosages were increased in 19.5% of cases (175,239 prescriptions). The unique aspect of this present study is that the prescriptions of patients who had undergone intensified therapy were compared with those who had not. Most of the patients in the intensified therapy group were prescribed a combination of two types (178,901 of 554,320 visits; 32.3%) or three types (175,989 of 554,320 visits; 31.7%) of drug. However, in the therapeutic inertia group, during 67.1% (231,444 of 344,815 visits) of the visits the patients were prescribed with one or two types of medication. Academic studies or treatment guidelines for chronic diseases such as high blood pressure, dyslipidaemia, and diabetes mellitus, indicate that complications can be prevented or delayed if the disease is adequately controlled. According to the treatment recommendations for type 2 diabetes from the Taiwan Diabetes Society, prescribing a low-dose combination of drugs rather than a high dose of a single type of drug is more effective in lowering blood glucose and alleviating the side-effects of the medications.

This present study had several limitations. First, the study population was highly specific, focusing on the DM-P4P population rather than the entire population of patients with diabetes mellitus in Taiwan. A previous study reported that patients who present with comorbidities or severe diseases are more likely to be excluded from DM-P4P programmes. Secondly, the study was unable to collect data on patient adherence to the prescribed therapy. Thirdly, the study concentrated on whether physicians chose to intensify treatment for poorly controlled blood glucose levels through the use of hypoglycaemic drugs. Other measures of health care such as the risk of hypoglycaemia, type of drugs selected, increase in dosage, dietary habits of patients, and referral to care teams were not considered in this study. Nevertheless, the large patient population in the validated nationwide database should be considered as a representative sample, and should thus provide a reliable clinical representation of diabetes care in routine practice in Taiwan.

In conclusion, this is the first study in Taiwan that has linked HbA1c results to antidiabetic drug prescribing patterns. By analysing changes in prescriptions before and after HbA1c test results, this present study sought to determine whether physicians modified prescriptions within 120 days of receiving abnormal HbA1c results (i.e., > 7%). These findings suggest that changes in drug prescriptions for patients with poorly controlled blood glucose levels could be used as an indicator of health care quality. For patients with HbA1c over 7%, a high proportion of those in the intensified therapy group were prescribed a combination of drugs, indicating that these patients were receiving adequate clinical care. In the therapeutic inertia group, however, the study observed that in many cases only a single type of hypoglycaemic drug was prescribed or the dosage remained unchanged. Further studies are necessary to clarify the relationship between
therapeutic inertia and efforts to maintain glycaemic control.

**Author contributions**
The conception and design of the study, or acquisition of data, or analysis and interpretation of the data were performed by L.Y.H., W.Y.S., M.C.Y., H.L.Y., S.S., and M.S.L.

**Declaration of conflicting interests**
The authors declare that there are no conflicts of interest.

**Funding**
The authors thank the Bureau of National Health Insurance for financial support (No. DOH101-NH-9014).

**References**

1. Wild S, Roglic G, Green A, et al. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. *Diabetes Care* 2004; 27: 1047–1053.
2. *International Diabetes Federation Diabetes Atlas update poster*. 6th ed. Brussels, Belgium: International Diabetes Federation, www.idf.org/diabetesatlas (2014, accessed 17 May 2015).
3. Chan JC, Malik V, Jia W, et al. Diabetes in Asia: epidemiology, risk factors, and pathophysiology. *JAMA* 2009; 301: 2129–2140.
4. Davis J, Chavez B and Juarez DT. Adjustments to diabetes medications in response to increases in hemoglobin a1c: an epidemiologic study. *Ann Pharmacother* 2014; 48: 41–47.
5. Hoerger TJ, Segel JE, Gregg EW, et al. Is glycemic control improving in U. S. adults? *Diabetes Care* 2008; 31: 81–86.
6. Huang LY, Shau WY, Yeh HL, et al. A model measuring therapeutic inertia and the associated factors among diabetes patients: A nationwide population-based study in Taiwan. *J Clin Pharmacol* 2015; 55: 17–24.
7. Reach G. *Clinical inertia. A critique of medical reason*. Switzerland: Springer International Publishing, 2015, pp.5–12.
8. Phillips LS, Branch WT, Cook CB, et al. Clinical inertia. *Ann Intern Med* 2001; 135: 825–834.
9. Andrade SE, Gurwitz JH, Field TS, et al. Hypertension management: the care gap between clinical guidelines and clinical practice. *Am J Manag Care* 2004; 10(7 Pt 2): 481–486.
10. Lee TT, Cheng SH, Chen CC, et al. A pay-for-performance program for diabetes care in Taiwan: a preliminary assessment. *Am J Manag Care* 2010; 16: 65–69.
11. Cheng SH, Lee TT and Chen CC. A longitudinal examination of a pay-for-performance program for diabetes care: evidence from a natural experiment. *Med Care* 2012; 50: 109–116.
12. Chen TT, Chung KP, Lin IC, et al. The unintended consequence of diabetes mellitus pay-for-performance (P4P) program in Taiwan: are patients with more comorbidities or more severe conditions likely to be excluded from the P4P program. *Health Serv Res* 2011; 46(1 Pt 1): 47–60.
13. Chang RE, Lin SP and Aron DC. A pay-for-performance program in Taiwan improved care for some diabetes patients, but doctors may have excluded sicker ones. *Health Aff (Millwood)* 2012; 31: 93–102.
14. Greenfield S, Kaplan SH, Kahn R, et al. Profiling care provided by different groups of physicians: effects of patient case-mix (bias) and physician-level clustering on quality assessment results. *Ann Intern Med* 2002; 136: 111–121.
15. ICD-9-CM Index to Diseases and Injuries Addenda Effective October 1, 2011, http://www.cdc.gov/nchs/data/icd/icd-9-cmindex-addenda912.pdf (2011, accessed 17 May 2015).
16. Lin CC, Lai MS, Syu CY, et al. Accuracy of diabetes diagnosis in health insurance claims data in Taiwan. *J Formos Med Assoc* 2005; 104: 157–163.
17. Meduru P, Helmer D, Rajan M, et al. Chronic illness with complexity: implications for performance measurement of optimal glycemic control. *J Gen Intern Med* 2007; 22(Suppl 3): 408–418.
18. Griffith ML, Boord JB, Eden SK, et al. Clinical inertia of discharge planning among
patients with poorly controlled diabetes mellitus. *J Clin Endocrinol Metab* 2012; 97: 2019–2026.

19. The anatomical therapeutic chemical classification system and the defined daily dose. Internet database. WHO Collaborating Centre for Drug Statistics Methodology, Norwegian Institute of Public Health. Nydalen, Oslo, Norway. http://www.whoce.no/atc_ddd_index/ (2015, accessed 17 May 2015).

20. Teoh H, Home P and Leiter LA. Should A1C targets be individualized for all people with diabetes? Arguments for and against. *Diabetes Care* 2011; 34 (Suppl 2): S191–S196.

21. Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. *Diabetes Care* 2009; 32: 193–203.

22. NICE clinical guideline CG87 Type 2 Diabetes - newer agents (partial update of CG66), http://www.nice.org.uk.CG87 (2009, accessed 17 May 2015).

23. NICE clinical guideline CG66 Type 2 Diabetes - the management of type 2 diabetes, https://www.nice.org.uk/guidance/cg66 (2008, accessed 17 May 2015).

24. Grant RW, Buse JB and Meigs JB. Quality of diabetes care in U.S. academic medical centers: low rates of medical regimen change. *Diabetes Care* 2005; 28: 337–442.

25. The reimbursement for diabetes-related medical treatment in Taiwan. http://www.nhi.gov.tw/Resource/bulletin/6342_1050055307A-2.pdf (2016, accessed 11 August 2016).

26. Rodondi N, Peng T, Karter AJ, et al. Therapy modifications in response to poorly controlled hypertension, dyslipidemia, and diabetes mellitus. *Ann Intern Med* 2006; 144: 475–484.

27. American Diabetes Association. Standards of medical care in diabetes–2013. *Diabetes Care* 2013; 36(Suppl 1): S11–S66.

28. The management of diabetes. The Diabetes Association of the Republic of China (Taiwan), http://www.endo-dm.org.tw/dia/direct/index.asp?BK_KIND=26 (2015, accessed 12 August 2016).